Try a new search

Format these results:

Searched for:

in-biosketch:true

person:natalj05

Total Results:

37


Perioperative Lactate, Survival, and Complications Following Lung Transplantation

Drozdowicz, Kelly A; Wadowski, Benjamin; Phillips, Katherine G; James, Les; Angel, Luis; Natalini, Jake G; Rudym, Darya; Qayum, Seema; Lesko, Melissa; Grossi, Eugene A; Geraci, Travis C; Chang, Stephanie H; Chan, Justin C Y
OBJECTIVES/OBJECTIVE:To examine perioperative lactate and its association with survival and postoperative complications following lung transplantation (LTx). DESIGN/METHODS:Single-center retrospective cohort study. SETTING/METHODS:Academic tertiary-care transplant center. PARTICIPANTS/METHODS:Adult patients undergoing LTx between February 2018 and January 2023. INTERVENTIONS/METHODS:None. MEASUREMENTS AND MAIN RESULTS/RESULTS:Serum lactate was measured at 6-hour intervals from the start of surgery, and the maximum value within the first 0 to 6 hours was recorded. Patients were categorized into the high-lactate group (upper quartile, ≥4.2 mmol/L) and low-lactate group (lower 3 quartiles). Primary outcomes were 1-year and overall survival. Secondary outcomes included renal failure, venous thromboembolism (VTE), primary graft dysfunction grade 3 (PGD3), mechanical ventilation duration, intensive care unit (ICU) and post-transplant length of stay, and in-hospital mortality. Among 225 recipients (median age, 62.3 years; 34.2% female), high lactate was not associated with 1-year or overall survival. However, recipients with high lactate had higher rates of PGD3 at 72 hours (42.1% v 13.1%, p < 0.001), longer mechanical ventilation duration (3 days v 2 days, p = 0.003), longer ICU stay (11.6 days v 7 days, p = 0.013), and higher in-hospital mortality rate (7% v 0.6%, p = 0.019). No significant differences were observed in renal failure, VTE, or post-transplant length of stay. CONCLUSIONS:Elevated perioperative serum lactate was associated with PGD3 at 72 hours, prolonged mechanical ventilation, longer ICU stay, and in-hospital mortality but not 1-year or overall survival following LTx. These findings suggest that perioperative lactate may aid in identifying high-risk patients early in their postoperative course despite its lack of association with long-term survival.
PMID: 42951749
ISSN: 1532-8422
CID: 6074780

Lung Utilization and Transplant Outcomes after Donor Management at an In-Hospital Donor Care Unit versus the Donor Hospital

Stewart, Darren E; Sommer, Philip M; Victoria Davis, N P; Chang, Stephanie H; Natalini, Jake G; Piper, Greta L; Mehta, Sapna A; McBride, Jennifer P; Boulton, Gabriella C; Lesko, Melissa B; Massie, Allan B; Segev, Dorry L; Montgomery, Robert A; Angel, Luis F
BACKGROUND:Fewer than 20% of donated lungs are transplanted. We examined the impacts of donor management and recovery at an in-hospital donor care unit (DCU) established in 2021 versus the donor hospital (DH). METHODS:(P/F ratio) were examined as a hypothesized effect modifier. We projected the national impact of improved utilization on lung transplant volume. RESULTS:After adjusting for donor differences, lung utilization was 88% higher (aRR: 1.88; 95% CI: 1.40, 2.53) in the DCU versus DH setting. Median P/F ratio increased from 275 to 348 mmHg (p<0.0001) in the DCU and explained approximately 38% of the improvement in lung utilization. Non-lung organ utilization was either improved or non-inferior in the DCU. Lung graft survival and pulmonary function were similar for recipients of DCU versus DH-managed donors. Nationally, an 88% improvement in lung utilization among donors not currently transferred to a DCU could theoretically result in ≥300 more lung transplants per year. CONCLUSIONS:Lung transplantation can be nearly doubled through lung-centric donor management in a DCU, without sacrificing recipient outcomes nor the utilization of other organs. Donor management practices to optimize lung utilization should be proliferated by establishing more DCUs and, where feasible, applying lung-centric protocols in donor hospitals.
PMID: 42764097
ISSN: 1557-3117
CID: 6073493

National Trends in Consent to Accept Hepatitis C Virus Positive Donor Organs

Massie, Priya; Xue, Ruiqi; Orandi, Babak J; Berger, Jonathan C; Torres-Hernandez, Alejandro; Moazami, Nader; Halazun, Karim J; Natalini, Jake G; Stewart, Darren E; Segev, Dorry L; Massie, Allan B; Lonze, Bonnie E
As hepatitis C virus (HCV) infection is now curable, HCV-positive donor organs have expanded the deceased donor pool. Using OPTN data, we identified adult kidney, liver, heart, and lung candidates listed between 2016-2025 and evaluated rates of consent to accept HCV antibody-positive (Ab+) and HCV viremic (NAT+) organs. Temporal trends were described, and multilevel modified Poisson regression with center-level random effects was used to estimate adjusted risk ratios for candidate factors and quantify center variation using median incidence rate ratios (MIRR). Rates of consent to accept both HCV Ab+ and NAT+ organs rose over time. By the end of follow-up, consent rates for HCV Ab+ organs were 63.1% for kidney, 80.6% for liver, 73.3% for heart, and 72.1% for lung candidates, and consent rates for NAT+ organs were 44.9%, 70.7%, 50.5%, and 46.1%, respectively. Associations between candidate characteristics and consent were small after adjustment for center, whereas center effects were large. For HCV Ab+ organs, MIRRs were 6.31 (kidney), 2.48 (liver), 2.90 (heart), and 4.36 (lung); for NAT+ organs, MIRRs were even higher, 9.65, 3.19, 4.00, and 7.30, respectively, indicating marked between-center variability. Our analyses suggest that access to HCV-positive organs is influenced more by center practices than patient characteristics.
PMID: 42716308
ISSN: 1600-6143
CID: 6072239

The utility of machine learning for predicting donor non-use in lung transplantation

Malik, Tahir Hafeez; Abdullah, Abiha; Tsai, Irene; Plascencia Jiménez, Jose A; Amesimeku, Etornam; Chang, Stephanie H; Angel, Luis F; Stewart, Darren; Seethamraju, Harish; Garcha, Puneet; Rana, Abbas; Natalini, Jake G
BACKGROUND/UNASSIGNED:Efforts to reduce waitlist mortality in lung transplantation have been hindered by a high donor lung non-use rate, with approximately one-fifth of deceased organ donors ultimately providing lungs for transplantation. Rationale for organ decline varies across individual providers and transplant centers. Greater donor lung utilization could significantly reduce waitlist mortality and improve clinical outcomes for adult lung transplant candidates. OBJECTIVE/UNASSIGNED:This study aimed to evaluate whether machine learning models can successfully predict donor lung non-use and characterize donor factors associated with current utilization patterns, with the long-term goal of informing more consistent and data-driven donor lung evaluation. METHODS/UNASSIGNED:Using U.S. national registry data collected between 2012 and 2022, we generated five machine learning models - logistic regression, decision tree, random forest, XGBoost, and Naive Bayes - all of which were trained with 19 donor variables to predict donor lung non-use. Models were tested with both full donor feature sets and restricted donor feature sets comprised of the top 15, 10, and 5 predictors. Performance metrics, including area under the receiver operating characteristic curve (AUROC), accuracy, precision, recall, and F1 score, were assessed using cross-validation. RESULTS/UNASSIGNED:ratio, donor age, body mass index, and serum aspartate aminotransferase levels. More restricted random forest models (i.e., those that only included 5 or 10 predictors) and any of the restricted logistic regression and XGBoost models had inferior but still acceptable performance (AUROC 0.867-0.958). CONCLUSION/UNASSIGNED:Machine learning models, particularly random forest, XGBoost, and logistic regression, accurately predicted donor lung non-use. Restricted models using fewer predictors also maintained strong performance, demonstrating technical feasibility for future evaluation in time-sensitive workflows. Because the models were trained on historical utilization decisions rather than recipient outcomes or independent measures of donor suitability, prospective validation is needed to determine whether they can improve appropriate donor lung utilization or support acceptance decisions without reinforcing practice-pattern bias.
PMCID:13473938
PMID: 42602439
ISSN: 2950-1334
CID: 6071323

Waitlist outcome differences for pulmonary hypertension patients are worse in the CAS era

Sonnick, Mark A; Laothamatas, Kemarut C; Anderson, Michaela R; Stewart, Darren; Natalini, Jake G; Arcasoy, Selim M; Benvenuto, Luke
BACKGROUND/UNASSIGNED:Patients with pulmonary hypertension (PH) have previously experienced worse waitlist outcomes than peers with other diagnoses. In 2021, the Lung Allocation Score (LAS) was revised to improve the prediction of expected survival. The Composite Allocation Score (CAS) was subsequently implemented in 2023. The effects of these changes on waitlist outcomes for patients with PH are not known. METHODS/UNASSIGNED:A retrospective analysis of the United Network for Organ Sharing database was performed in 3 eras: LAS Era 1 (November 24, 2017-September 30, 2021), LAS Era 2 (October 1, 2021-March 8, 2023), and CAS Era (March 9, 2023-June 27, 2024). Unadjusted and adjusted competing risks regression analyzed waitlist outcomes within each era comparing diagnosis groups, and for PH patients across eras. RESULTS/UNASSIGNED:Adjusted waitlist mortality for PH patients was worse relative to chronic obstructive pulmonary disease (COPD) and cystic fibrosis in LAS Era 1, not significantly different from other groups in LAS Era 2, and worse relative to COPD and interstitial lung disease in the CAS Era. Waitlist mortality for PH patients was unchanged between the LAS Eras and the CAS Era. Transplantation rate for PH patients was improved in the CAS Era compared to LAS Era 2, when measures of right heart dysfunction were removed from the LAS calculations, but not compared to LAS Era 1. CONCLUSION/UNASSIGNED:In the CAS Era, PH patients continue to experience increased waitlist mortality relative to non-PH diagnoses. Waitlist mortality for PH patients has not improved in the CAS Era compared to the LAS Eras.
PMCID:12723166
PMID: 41446011
ISSN: 2950-1334
CID: 6041982

Utility of donor-derived cell-free DNA testing after lung transplantation in the precision medicine era

Keller, Brian C; Agbor-Enoh, Sean; Keller, Michael B; Nandavaram, Sravanthi; Zeevi, Adriana; McDyer, John F; Hays, Steven R; Samuel Weigt, S; Belperio, John A; Sayah, David M; Aryal, Shambhu; Orens, Jonathan B; Trindade, Anil J; Shaver, Ciara M; Yeung, Jonathan C; Keshavjee, Shaf; Martinu, Tereza; Crespo, Maria M; Christie, Jason D; Diamond, Joshua M; Arcasoy, Selim M; Tomic, Rade; Sanchez, Pablo G; Byers, Derek E; Palmer, Scott M; Halloran, Kieran; Gray, Alice L; Dilling, Daniel F; Natalini, Jake G; Gries, Cynthia J; Budev, Marie M; Sharma, Nirmal S; Ross, David J; Bhorade, Sangeeta; Berry, Gerald J; Khush, Kiran K; Woodward, Robert N; Gray, Jennifer N; Ensor, Christopher R; Levine, Deborah J
Donor-derived cell-free DNA (dd-cfDNA) is a validated, highly sensitive, plasma molecular biomarker of allograft injury after solid organ transplantation. Robust experiences with dd-cfDNA testing after kidney and heart transplantation have generated interest in this biomarker within the lung transplantation (LTx) community. A growing body of evidence now provides increased insight into dd-cfDNA utility for molecular monitoring of lung allograft health after transplantation. The expanding understanding of lung allograft injury to appropriately frame the advancing role of dd-cfDNA in the evolution of the diagnostic approach after LTx is described. Performance characteristics of both laboratory-based shotgun-sequenced testing from the Genome Transplant Dynamics (GTD) and Genomic Research Alliance for Transplantation (GRAfT) consortia, as well as commercially available central lab-based algorithmic next-generation sequenced dd-cfDNA tests for lung transplant recipients (LTR) (AlloSure, CareDx and Prospera, Natera) are described. Kinetics of dd-cfDNA in LTRs over time, in multiple different clinical scenarios, from several investigator groups are aggregated. Phenotypes of lung allograft injury, such as acute lung allograft dysfunction, and associated dd-cfDNA patterns and performance are identified in alignment with established definitions and evolving molecular injury insights. Certain patterns of molecular injury that may predict long-term outcomes including chronic lung allograft dysfunction and mortality are examined. Lastly, clinical approaches to testing and interpretation of dd-cfDNA results in LTRs, a practical approach to using dd-cfDNA, and a rational framework for interpreting dd-cfDNA results in LTRs are presented.
PMID: 41991095
ISSN: 1557-3117
CID: 6028142

Lower Airway Dysbiosis in NTM+ Bronchiectasis is Associated with NET-Predominant Severe Phenotypes

Singh, Shivani; Darawshy, Fares; Erlandson, Kirby; Narayana, Jayanth Kumar; Li, Qingsheng; Li, Yonghua; Atandi, Isabella; Krolikowski, Kelsey; Patel, Shrey; Collazo, Destiny; Mac Aogáin, Micheál; Gilmour, Amy; Long, Merete; Chang, Miao; Hoque, Afshana; Schluger, Rosemary; Kumar, Sanjan; Chung, Cecilia J; Wong, Kendrew; Porter, Gabriella; Feng, Yicheng; Czachor, Anna; McCormick, Colin; Clementi, Emily; Kyeremateng, Yaa; Lukovnikova, Alena; Harris, Danielle; Gomez, Sebastian; Kain, Taylor; Kocak, Ibrahim; Singh, Rajbir; Rodriguez, Claudia; Kwok, Benjamin; Barnett, Clea; Kugler, Matthias; Weiden, Michael D; Nelson, Nathaniel; Natalini, Jake G; Luglio, David; Desvignes, Ludovic; Gautam, Samir; McGuire, Erin; Gordon, Terry; Sulaiman, Imran; Tsay, Jun-Chieh J; Basavaraj, Ashwin; Wu, Benjamin G; Kamelhar, David; Addrizzo-Harris, Doreen; Chalmers, James D; Chotirmall, Sanjay H; Segal, Leopoldo N
RATIONALE/BACKGROUND:The discoveries of neutrophilic inflammation and Pseudomonas-dominant pulmonary dysbiosis have helped pave the way for host-directed therapy in bronchiectasis. Substantial knowledge gaps still remain about the interplay between neutrophilic signatures and microbes in non-tuberculous mycobacterial lung disease (NTM-LD), a phenotypically diverse lung infection that is increasingly prevalent in the United States and other parts of the world. OBJECTIVES/OBJECTIVE:Evaluate the lower airway microbiota and neutrophilic traits in NTM- and NTM+ bronchiectasis. METHODS:16S rRNA gene sequencing, cell counts, and neutrophil extracellular trap (NET) immunoassays were performed on bronchoscopic lower airway samples in 200 bronchiectasis subjects (108 NTM-, 92 NTM+). A preclinical model of oral commensal micro-aspiration and NTM infection was used to profile the murine lower airways with flow cytometry and a NET assay. MEASUREMENTS AND MAIN RESULTS/RESULTS:Lower airways of NTM+ bronchiectasis patients were enriched with Mycobacterium and oral commensals (e.g., Veillonella, Prevotella and Streptococcus). NET levels were higher in NTM+ BAL. Mycobacterium and oral commensals co-occurred with NET and neutrophils in network studies. Distinct oral commensal taxa were associated with severe disease phenotypes such as cavitary disease and exacerbators. In a murine micro-aspiration model, the combination of oral commensals and Mycobacterium led to a sustained pro-inflammatory immune response marked by an increase in Th17, γδT cells, PD-1+ T lymphocytes as well as higher NET levels. CONCLUSIONS:Our analyses showed that distinct microbiome features beyond the primary pathogen can contribute to neutrophilic inflammation and severe disease phenotypes in bronchiectasis/ NTM-LD.
PMID: 41738242
ISSN: 1535-4970
CID: 6010022

Impact of Intraoperative Albumin Use During Lung Transplantation on Primary Graft Dysfunction

Tatsuoka, Yoshio; Zembrzuski, Krzysztof J; Natalini, Jake G; Chang, Stephanie H; Ngai, Jennie Y
PMCID:12608215
PMID: 41227239
ISSN: 2077-0383
CID: 5966912

Microbial contribution to metabolic niche formation varies across the respiratory tract

Wong, Kendrew K; Wu, Benjamin G; Chung, Matthew; Li, Qinsheng; Darawshy, Fares; Tsay, Jun-Chieh J; Holub, Meredith; Barnett, Clea R; Kwok, Benjamin; Kugler, Matthias C; Chung, Cecilia; Natalini, Jake G; Singh, Shivani; Li, Yonghua; Schluger, Rosemary; Ficaro, Lia; Carpenito, Joseph; Collazo, Destiny; Perez, Luisanny; Kyeremateng, Yaa; Chang, Miao; Czachor, Anna; Singh, Raj; Mccormick, Colin; Campbell, Christina D; Keane, Ruaidhri; Askenazi, Manor; Hansbro, Philip M; Weiden, Michael D; Huang, Yvonne J; Stringer, Kathleen A; Clemente, Jose C; Li, Huilin; Jones, Drew; Ghedin, Elodie; Segal, Leopoldo N; Sulaiman, Imran
Variations in the airway microbiome are associated with inflammatory responses in the lung and pulmonary disease outcomes. Regional changes in microbiome composition could have spatial effects on the metabolic environment, contributing to differences in the host response. Here, we profiled the respiratory microbiome (metagenome/metatranscriptome) and metabolome of a patient cohort, uncovering topographical differences in microbial function, which were further delineated using isotope probing in mice. In humans, the functional activity of taxa varied across the respiratory tract and correlated with immunomodulatory metabolites such as glutamic acid/glutamate and methionine. Common oral commensals, such as Prevotella, Streptococcus, and Veillonella, were more functionally active in the lower airways. Inoculating mice with these commensals led to regional increases in several metabolites, notably methionine and tyrosine. Isotope labeling validated the contribution of Prevotella melaninogenica in generating specific metabolites. This functional characterization of microbial communities reveals topographical changes in the lung metabolome and potential impacts on host responses.
PMID: 40578342
ISSN: 1934-6069
CID: 5883232

Graft Survival in Single versus Bilateral Lung Transplantation for Emphysema

Stewart, Darren E; Ruck, Jessica M; Massie, Allan B; Segev, Dorry L; Lesko, Melissa B; Chan, Justin C; Chang, Stephanie H; Geraci, Travis C; Rudym, Darya; Sonnick, Mark A; Barmaimon, Guido; Angel, Luis F; Natalini, Jake G
The benefits of bilateral lung transplantation (BLT) versus single lung transplantation (SLT) are still debated. One impediment to clinical recommendations is that BLT vs. SLT advantages may vary based on underlying disease. Since both options are clinically tenable in patients with emphysema, we conducted a comprehensive assessment of lung allograft survival in this population. Using U.S. registry data, we studied time to all-cause allograft failure in 8,092 patients 12 years or older transplanted from 2006 to 2022, adjusting for recipient, donor, and transplant factors by inverse propensity weighting. Median allograft survival was 6.6 years in BLT compared to 5.3 years in SLT, a 25% risk-adjusted survival advantage of 0.81.31.8 years. Risk-adjusted bilateral survival advantages varied between 0.9 and 2.4 years across eleven subgroups. Median allograft survival in BLT was 1.2 years greater than right SLT and 2.0 years greater than left SLT. During the 16-year study period, allograft survival steadily improved for BLT but not for SLT. Although the 25% BLT survival advantage pre-dated the pandemic, COVID-19 may have contributed to an apparent SLT survival decline. Recognizing the possible influence of residual confounding due to selection biases, these findings may aid offer decision-making when both donor lungs are available.
PMID: 40419023
ISSN: 1600-6143
CID: 5855112